Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$56.13−0.03 (-0.05%)
Close on Nov 13, 2026Market cap $7.80BP/E –Yield –
Cytokinetics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cytokinetics's ebitda for the twelve months ending Sep 30, 2026 was -$694.73M. For fiscal 2025 it was -$602.13M. The highest annual figure on record is $28.12M in fiscal 2009.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$602.13M | – |
| FY2024 | Dec 31, 2024 | -$526.72M | – |
| FY2023 | Dec 31, 2023 | -$484.31M | – |
| FY2022 | Dec 31, 2022 | -$318.39M | – |
| FY2021 | Dec 31, 2021 | -$184.04M | – |
| FY2020 | Dec 31, 2020 | -$92.11M | – |
| FY2019 | Dec 31, 2019 | -$97.57M | – |
| FY2018 | Dec 31, 2018 | -$87.68M | – |
| FY2017 | Dec 31, 2017 | -$111.48M | -673.8% |
| FY2016 | Dec 31, 2016 | $19.43M | – |
| FY2015 | Dec 31, 2015 | -$36.82M | – |
| FY2014 | Dec 31, 2014 | -$14.26M | – |
| FY2013 | Dec 31, 2013 | -$33.46M | – |
| FY2012 | Dec 31, 2012 | -$39.87M | – |
| FY2011 | Dec 31, 2011 | -$46.67M | – |
| FY2010 | Dec 31, 2010 | -$47.74M | -269.8% |
| FY2009 | Dec 31, 2009 | $28.12M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$163.44M | – |
| Q2 FY2026 | Jun 30, 2026 | -$175.54M | – |
| Q1 FY2026 | Mar 31, 2026 | -$180.24M | – |
| Q4 FY2025 | Dec 31, 2025 | -$175.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$164.08M | – |
| Q2 FY2025 | Jun 30, 2025 | -$109.22M | – |
| Q1 FY2025 | Mar 31, 2025 | -$153.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$136.66M | – |
| Q3 FY2024 | Sep 30, 2024 | -$138.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$127.77M | – |
| Q1 FY2024 | Mar 31, 2024 | -$123.90M | – |
| Q4 FY2023 | Dec 31, 2023 | -$121.08M | – |
| Q3 FY2023 | Sep 30, 2023 | -$120.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -$120.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$122.63M | – |
| Q4 FY2022 | Dec 31, 2022 | -$125.37M | – |
| Q3 FY2022 | Sep 30, 2022 | -$107.03M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.47M | – |
| Q1 FY2022 | Mar 31, 2022 | -$76.52M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.97M | – |
| Q3 FY2021 | Sep 30, 2021 | -$68.74M | -1301.7% |
| Q2 FY2021 | Jun 30, 2021 | -$54.25M | – |
| Q1 FY2021 | Mar 31, 2021 | -$40.07M | – |
| Q4 FY2020 | Dec 31, 2020 | -$35.94M | – |
| Q3 FY2020 | Sep 30, 2020 | $5.72M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.94M | – |
| Q1 FY2020 | Mar 31, 2020 | -$29.95M | – |
| Q4 FY2019 | Dec 31, 2019 | -$23.32M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.59M | – |
| Q2 FY2019 | Jun 30, 2019 | -$26.44M | – |
| Q1 FY2019 | Mar 31, 2019 | -$24.23M | – |
| Q4 FY2018 | Dec 31, 2018 | -$21.78M | – |
| Q3 FY2018 | Sep 30, 2018 | -$17.65M | – |
| Q2 FY2018 | Jun 30, 2018 | -$22.80M | -388.1% |
| Q1 FY2018 | Mar 31, 2018 | -$25.46M | – |
| Q2 FY2017 | Jun 30, 2017 | -$24.76M | – |
| Q1 FY2017 | Mar 31, 2017 | -$22.83M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.91M | – |
See a number that looks wrong?